Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Post by eSnowdenon Nov 12, 2015 8:25am
200 Views
Post# 24284092

No Worries here...

No Worries here...Acerus has been hitting new 52 week lows with every trading day for the past week. Estrace sales are still below the sales when it was acquired (even with "double digit" growth.) and our other product has a delivery tech that no other sane pharma would even attempt (i.e. up the nose.) Endo probably wants a portion of the $25mm returned given the "non-performance" of natesto. 

Rossi hides so much material stuff, you really don't know what's going on. What were the real terms of the Endo deal? How are meetings with the FDA going? Even the former CFO knew to get out of dodge.
Bullboard Posts